Longboard Pharmaceuticals
Clinical trials sponsored by Longboard Pharmaceuticals, explained in plain language.
-
New hope for dravet syndrome: phase 3 trial targets seizure control
Disease control Recruiting nowThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with Dravet syndrome, a severe form of epilepsy. About 160 participants will receive either LP352 or a placebo, and researchers will track changes in seizure frequenc…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:51 UTC
-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Symptom relief Recruiting nowThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Symptom relief
Last updated May 26, 2026 10:45 UTC